Navigation Links
VIVUS Reports Second Quarter and First Six Months 2011 Financial Results
Date:8/1/2011

om this study will be used as part of the QNEXA New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA).

The Marketing Authorization Application (MAA) for QNEXA was submitted to the European Medicines Agency (EMA) in December 2010.  In May of 2011 we received the 120-day list of questions from the Committee for Medicinal Products for Human Use (CHMP) and began preparing our response.  The questions and issues raised by the CHMP were consistent with those raised by the FDA.  We have requested and have been granted a meeting with the rapporteur September 2011 to discuss the 120-day questions.  The purpose of this meeting is to provide clarification to certain questions to assist us in preparing our response.  Our response to the 120-day questions is expected in the fourth quarter of 2011.

"The FORTRESS protocol has been reviewed and approved by the FDA.  The results of the retrospective study announced in July 2011 and Danish study published in the May 2011 issue of the Journal of the American Medical Association both concluded that topiramate was not a major teratogen. We look forward to the FORTRESS results and resubmission of the QNEXA NDA in the fourth quarter of 2011," stated Peter Tam, president of VIVUS.

Avanafil UpdateIn June 2011, we submitted an NDA to the FDA seeking approval of avanafil, our investigational drug for the treatment of erectile dysfunction (ED). The NDA submission follows the successful completion of an extensive phase 3 program for avanafil, which included over 1,350 patients, where avanafil was shown to be well tolerated and effective in treating men with ED.

"The highlight of the second quarter was the filing of the NDA for avanafil.  Congratulations to all of the members of the avanafil development team who worked diligently to achieve this significant corporate milestone.  In a large and growing market, avanafil, if approved, shou
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. VIVUS Reports 2010 Fourth Quarter and Full-Year Financial Results
2. VIVUS to Present at Three Upcoming Investor Conferences in March
3. VIVUS Provides Regulatory Update on QNEXA NDA
4. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
6. VIVUS to Present at Two Upcoming Investor Conferences
7. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
8. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
9. VIVUS Announces Sale of MUSE Assets to Meda
10. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
11. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... its public offering of 4,500,000 shares of its common stock ... per share. Aratana has granted the underwriters a ... 675,000 shares of its common stock. ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
Breaking Medicine Technology:Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... Texas, Sept. 26, 2011 Vermillion, Inc. ... today announced the appointment of Donald Munroe, Ph.D. as ...  He will be responsible for furthering development of Vermillion,s ... continue the preclinical studies and initiate appropriate clinical studies ...
... SAN DIEGO, Sept. 26, 2011 Elevation Pharmaceuticals, Inc., ... aerosol therapies for patients with respiratory diseases, today announced ... and Chief Business Officer and Pravin Soni, PhD, as ... created positions. The company also announced that it drew ...
Cached Medicine Technology:Vermillion Enhances Management Team With A Key Addition 2Vermillion Enhances Management Team With A Key Addition 3Vermillion Enhances Management Team With A Key Addition 4Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives 2Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives 3
(Date:9/17/2014)... 17, 2014 (HealthDay News) -- A blood test that ... doctors with a better assessment of the state of ... If used routinely, this blood test could reveal when ... actually begins promoting tumor growth, the researchers suggested. ... patients with advanced prostate cancer and often initially very ...
(Date:9/17/2014)... this month for the November elections, one of the ... out the chamber door will be the Sustainable Growth ... of 2014. In a new commentary in the journal ... he and other advocates saw as the merits of ... Medicare pays doctors will return for the next Congress, ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 Many countries ... influenza, instead of immunizations. The total number of poultry ... difficult to control, will result in huge losses. Therefore, ... avian influenza vaccines. , Avian influenza vaccines have been ... poultry farms in China began to use H5N1 avian ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Smart Flour ... Picks by Progressive Grocer, a leading trade magazine targeted ... awarded for originality and flavor, among other attributes. Smart ... an Editor’s Pick in the September print issue of ... website. , The pizza won based on its superior ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A petition ... ) in laparoscopic hysterectomies and other gynecological surgeries has ... to figures posted on Change.org, at least 84,908 supporters ... , According to a recent report from ABC News, ... by Dr. Hooman Noorchashm, after his wife, Dr. Amy ...
Breaking Medicine News(10 mins):Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Failed Medicare payments law remains relevant 2Health News:Failed Medicare payments law remains relevant 3Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Nears 85,000 Signatures, Bernstein Liebhard LLP Reports 4
... American Associations for Dental Research announced that its Journal ... Five-Year Scientific Impact Factor (SIF) from 4.195 to 4.389. In ... #1 in Article Influence. This news comes from the new ... Journal Citation Reports (JCR). This latest report also shows that ...
... researchers from Boston University School of Medicine (BUSM) and ... high rate of thyroid function testing in pregnant women. ... the Journal of Clinical Endocrinology & Metabolism , ... testing on pregnant women, approximately 80 percent of cases ...
... has discovered in young adult mice that a lone brain stem ... to specialized neurons and glia important types of brain cells ... new brain stem cells. A report on their study appears ... that the brain has the capacity to generate both neurons, which ...
... HealthDay Reporter , THURSDAY, June 30 (HealthDay News) -- The ... rooms for drinking-related injuries doubles over the July 4th weekend, ... sends a daily average of nearly 1,000 youth under 21 ... problems related to alcohol use, according to a report by ...
... Italy, 30 June 2011 Differences in male and female ... be more verbally fluent, have better manual dexterity and are ... the other hand often take less time parking their cars ... new city. The latter capacities, in which men tend to ...
... Insomnia is the most prevalent sleep disorder, affecting ... the United States on a weekly basis. ... ever, randomized, controlled clinical research study in the country ... Optimization is a non-invasive technology that helps the brain ...
Cached Medicine News:Health News:Journal of Dental Research increases its scientific impact factor 2Health News:BMC conducts high rates of thyroid testing in pregnant women, study finds 2Health News:Nervous system stem cells can replace themselves, give rise to variety of cell types, even amplify 2Health News:July 4 Weekend Dangerous for Underage Boys Who Drink: Report 2Health News:Sound localization at cocktail parties is easier for men 2Health News:Wake Forest Baptist conducts clinical study for insomnia using new technology 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: